Overview

Sorafenib/Docetaxel Dose Escalation Trial

Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to: 1.) Evaluate how your body reacts to sorafenib when taken daily (continuously) in combination with docetaxel given every 3 weeks, and to determine the safety of the two drugs together.2.) Measure your blood levels of sorafenib and docetaxel at specific times after taking the medications.
Phase:
Phase 1
Details
Lead Sponsor:
Bayer
Collaborators:
Amgen
Onyx Pharmaceuticals
Treatments:
Docetaxel
Niacinamide
Sorafenib